TG Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
TG Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | ||||||||||||||||||||||||||||||||||||||||||||||||||
| assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 129,126,000 | 132,139,000 | 179,894,000 | 195,822,000 | 82,910,000 | 75,477,000 | 92,933,000 | 150,902,000 | 97,009,000 | 61,469,000 | 102,304,000 | 109,860,000 | 147,073,000 | 185,676,000 | 298,887,000 | 326,512,000 | 401,707,000 | 471,514,000 | 553,439,000 | 254,154,000 | 260,512,000 | 52,051,000 | 112,637,000 | 44,675,000 | 57,228,000 | 64,349,000 | 41,958,000 | 70,718,000 | 105,672,000 | 82,896,000 | 56,717,847 | 91,842,167 | 77,602,363 | 95,637,572 | 25,031,280 | 29,156,521 | 28,577,832 | 36,478,420 | 55,061,329 | 65,461,940 | 60,300,086 | 86,004,445 | 55,713,784 | 53,225,799 | 37,077,977 | 49,596,327 | 649,686 | 2,032,655 | 4,790,589 | 8,689,792 |
| short-term investment securities | 122,744,000 | 144,101,000 | 131,106,000 | 145,219,000 | 134,342,000 | 134,308,000 | 124,575,000 | 78,257,000 | 47,896,000 | 78,241,000 | 59,374,000 | 66,082,000 | 48,636,000 | 47,525,000 | 15,876,000 | 30,338,000 | 41,752,000 | 52,334,000 | 51,987,000 | 15,058,000 | 26,284,000 | 27,798,000 | 27,776,000 | 27,748,000 | 28,125,000 | 26,848,000 | 27,024,000 | 20,573,000 | 26,181,000 | 27,998,810 | 8,808,930 | 13,823,332 | 19,853,860 | 31,445,616 | 25,680,319 | 22,224,258 | 22,166,512 | 28,701,209 | 31,765,910 | 19,131,437 | 23,062,034 | 14,009,644 | 7,959,652 | 3,901,783 | ||||||
| accounts receivable | 231,516,000 | 190,121,000 | 129,185,000 | 115,727,000 | 83,608,000 | 64,982,000 | 51,093,000 | 39,320,000 | ||||||||||||||||||||||||||||||||||||||||||
| inventories | 155,202,000 | 157,759,000 | 110,458,000 | 84,669,000 | 81,243,000 | 77,719,000 | 39,823,000 | 33,553,000 | ||||||||||||||||||||||||||||||||||||||||||
| other current assets | 25,374,000 | 20,390,000 | 15,716,000 | 32,632,000 | 5,336,000 | 12,081,000 | 11,088,000 | 4,458,000 | 2,359,000 | 2,954,000 | 3,136,000 | 4,020,000 | 2,884,000 | 2,502,000 | 2,950,000 | 4,804,000 | 1,083,000 | 641,000 | 1,536,000 | 1,944,000 | 611,000 | 864,000 | 987,000 | 1,464,000 | 439,000 | 526,000 | 816,000 | 978,000 | 436,789 | 796,283 | 927,657 | 1,057,715 | 216,397 | 500,564 | 649,738 | 730,523 | 308,327 | 457,918 | 548,776 | 701,862 | 173,952 | 258,721 | 197,855 | 359,885 | ||||||
| total current assets | 663,962,000 | 644,510,000 | 566,359,000 | 574,069,000 | 389,150,000 | 360,581,000 | 317,943,000 | 319,114,000 | 208,574,000 | 184,783,000 | 168,274,000 | 182,922,000 | 202,560,000 | 242,216,000 | 330,965,000 | 371,779,000 | 455,068,000 | 535,013,000 | 611,740,000 | 260,335,000 | 280,938,000 | 88,016,000 | 149,151,000 | 80,355,000 | 94,441,000 | 105,058,000 | 79,031,000 | 109,737,000 | 136,038,000 | 116,958,000 | 93,317,400 | 97,661,296 | 97,044,477 | 118,963,818 | 50,864,144 | 71,332,374 | 69,551,680 | 70,576,744 | 86,873,331 | 104,730,487 | 103,727,043 | 115,738,341 | 85,215,029 | 76,665,848 | 49,286,908 | 56,288,114 | 865,538 | 2,234,816 | 5,143,246 | 9,191,884 |
| restricted cash | 1,316,000 | 1,302,000 | 1,298,000 | 1,295,000 | 1,292,000 | 1,289,000 | 1,285,000 | 1,282,000 | 1,279,000 | 1,276,000 | 1,273,000 | 1,269,000 | 1,266,000 | 1,265,000 | 1,264,000 | 1,263,000 | 1,261,000 | 1,260,000 | 1,259,000 | 1,257,000 | 1,255,000 | 1,252,000 | 1,251,000 | 1,248,000 | 1,246,000 | 1,244,000 | 1,241,000 | 1,239,000 | 1,237,000 | 588,000 | 587,291 | 586,259 | 585,229 | 584,213 | 583,208 | 582,184 | 581,161 | 580,151 | 579,143 | 578,126 | 577,110 | 576,072 | 575,012 | |||||||
| long-term investment securities | 28,590,000 | 1,907,000 | 808,000 | 1,125,000 | 947,000 | 1,320,000 | 21,435,015 | 26,458,226 | 25,003,032 | 21,088,192 | 18,311,340 | 6,110,309 | 1,001,858 | |||||||||||||||||||||||||||||||||||||
| right of use assets | 6,718,000 | 6,927,000 | 7,151,000 | 7,411,000 | 7,663,000 | 7,906,000 | 8,050,000 | 8,271,000 | ||||||||||||||||||||||||||||||||||||||||||
| other noncurrent assets | 2,027,000 | 2,042,000 | 2,074,000 | 2,114,000 | 2,155,000 | |||||||||||||||||||||||||||||||||||||||||||||
| total assets | 702,613,000 | 656,689,000 | 577,690,000 | 586,014,000 | 401,207,000 | 373,323,000 | 329,587,000 | 331,067,000 | 220,854,000 | 197,358,000 | 193,572,000 | 217,891,000 | 251,666,000 | 303,028,000 | 379,629,000 | 409,687,000 | 481,400,000 | 548,699,000 | 625,642,000 | 273,856,000 | 294,621,000 | 101,849,000 | 163,014,000 | 93,327,000 | 106,585,000 | 117,538,000 | 83,616,000 | 114,374,000 | 140,715,000 | 120,994,000 | 97,381,536 | 101,781,514 | 101,197,751 | 123,256,432 | 54,781,547 | 75,687,094 | 94,797,540 | 100,062,519 | 113,473,201 | 127,407,138 | 123,605,281 | 117,269,251 | 86,746,890 | 77,544,253 | 56,302,299 | 58,173,955 | 980,577 | 2,357,794 | 5,276,656 | 9,336,522 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| accounts payable and accrued expenses | 134,021,000 | 133,932,000 | 58,296,000 | 101,407,000 | 93,472,000 | 87,266,000 | 38,471,000 | 39,741,000 | 62,945,000 | 57,092,000 | 42,019,000 | 29,726,000 | 37,224,000 | 49,668,000 | 51,294,000 | 44,702,000 | 40,228,000 | 42,837,000 | 37,014,000 | 34,659,000 | 29,670,000 | 30,903,000 | 30,041,000 | 31,780,000 | 31,498,000 | 40,199,000 | 36,377,000 | 37,917,000 | 35,394,000 | 32,513,000 | 25,877,218 | 18,179,772 | 19,556,942 | 18,916,064 | 15,267,668 | 15,550,129 | 13,080,176 | 8,139,440 | 9,346,068 | 8,583,003 | 8,254,189 | 8,880,438 | 3,991,625 | 7,967,548 | 1,899,389 | 1,639,114 | ||||
| other current liabilities | 2,256,000 | 2,947,000 | 4,627,000 | 3,298,000 | 4,162,000 | 4,064,000 | 1,631,000 | 1,217,000 | 44,035,000 | 21,478,000 | 18,626,000 | |||||||||||||||||||||||||||||||||||||||
| lease liability – current portion | 1,091,000 | 1,116,000 | 1,157,000 | 1,231,000 | 1,306,000 | 1,383,000 | 1,446,000 | 1,479,000 | 1,365,000 | 1,283,000 | 1,261,000 | |||||||||||||||||||||||||||||||||||||||
| deferred revenue - current portion | 23,911,000 | 17,079,000 | 11,414,000 | 9,093,000 | 3,373,000 | 3,373,000 | 6,903,000 | |||||||||||||||||||||||||||||||||||||||||||
| accrued compensation | 10,610,000 | 5,135,000 | 15,185,000 | 10,085,000 | 6,351,000 | 3,598,000 | 12,172,000 | 8,338,000 | 6,641,000 | 3,217,000 | 8,432,000 | 4,298,000 | 2,882,000 | 1,623,000 | 10,166,000 | 12,858,000 | 8,514,000 | 3,537,000 | 8,456,000 | 5,072,000 | 3,440,000 | 1,368,000 | 3,798,000 | 3,017,000 | 1,708,000 | 854,000 | 2,258,000 | 2,082,000 | 1,182,000 | 456,000 | 1,800,000 | 1,275,305 | 896,805 | 483,555 | 1,389,516 | 1,061,626 | 796,376 | 449,126 | 818,472 | 768,750 | 506,000 | 248,000 | 702,000 | 599,083 | 395,500 | 197,250 | ||||
| total current liabilities | 171,889,000 | 160,209,000 | 90,679,000 | 125,114,000 | 108,664,000 | 99,684,000 | 53,720,000 | 57,678,000 | 72,667,000 | 63,076,000 | 53,201,000 | 36,447,000 | 43,326,000 | 54,656,000 | 65,384,000 | 87,655,000 | 87,551,000 | 92,494,000 | 87,554,000 | 77,670,000 | 67,537,000 | 63,118,000 | 84,449,000 | 80,197,000 | 55,967,000 | 60,940,000 | 38,854,000 | 40,242,000 | 36,938,000 | 33,345,000 | 27,957,213 | 19,789,614 | 20,758,696 | 19,726,657 | 16,878,440 | 16,881,262 | 14,119,497 | 8,893,864 | 10,528,470 | 9,685,802 | 9,207,930 | 9,553,025 | 5,121,196 | 8,902,156 | 2,606,484 | 1,988,745 | 1,791,146 | |||
| deferred revenue, non-current portion | 1,667,000 | 6,598,000 | 12,085,000 | 16,166,000 | 3,743,000 | 3,244,000 | 190,000 | |||||||||||||||||||||||||||||||||||||||||||
| loan payable – non-current | 245,037,000 | 244,733,000 | 244,158,000 | 102,537,000 | 101,326,000 | 98,908,000 | ||||||||||||||||||||||||||||||||||||||||||||
| lease liability – non-current | 7,588,000 | 7,860,000 | 8,133,000 | 8,419,000 | 8,695,000 | 8,960,000 | 9,231,000 | 9,522,000 | ||||||||||||||||||||||||||||||||||||||||||
| total liabilities | 426,181,000 | 419,400,000 | 355,326,000 | 393,857,000 | 223,639,000 | 213,214,000 | 169,085,000 | 166,298,000 | 180,401,000 | 169,925,000 | 134,985,000 | 117,410,000 | 122,631,000 | 132,642,000 | 142,476,000 | 98,170,000 | 98,270,000 | 103,414,000 | 106,292,000 | 103,198,000 | 100,394,000 | 103,202,000 | 124,399,000 | 119,118,000 | 93,380,000 | 98,284,000 | 59,580,000 | 42,630,000 | 39,339,000 | 35,762,000 | 30,388,481 | 22,235,748 | 23,222,733 | 22,214,673 | 18,913,745 | 18,932,373 | 16,096,455 | 10,616,751 | 11,899,899 | 11,095,326 | 10,655,549 | 11,038,739 | 6,645,006 | 10,464,061 | 4,206,484 | 3,742,394 | 1,871,662 | 2,530,255 | 2,192,910 | |
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| common stock | 159,000 | 159,000 | 156,000 | 156,000 | 155,000 | 155,000 | 151,000 | 151,000 | 151,000 | 149,000 | 146,000 | 145,000 | 145,000 | 145,000 | 143,000 | 143,000 | 143,000 | 142,000 | 141,000 | 129,000 | 127,000 | 110,000 | 109,000 | 97,000 | 93,000 | 89,000 | 84,000 | 83,000 | 82,000 | 77,000 | 73,182 | 70,694 | 68,127 | 66,817 | 56,820 | 54,766 | 54,498 | 54,119 | 54,095 | 52,558 | 51,698 | 47,472 | 44,974 | 41,481 | 38,162 | 37,526 | 70,624 | 70,624 | 70,474 | |
| additional paid-in capital | 1,794,212,000 | 1,776,381,000 | 1,760,396,000 | 1,746,909,000 | 1,734,052,000 | 1,685,256,000 | 1,674,946,000 | 1,664,797,000 | 1,654,411,000 | 1,593,783,000 | 1,585,708,000 | 1,574,609,000 | 1,567,345,000 | 1,568,186,000 | 1,565,942,000 | 1,546,967,000 | 1,532,943,000 | 1,516,602,000 | 1,500,040,000 | 1,063,142,000 | 999,549,000 | 751,103,000 | 739,956,000 | 635,989,000 | 613,059,000 | 582,900,000 | 552,531,000 | 546,380,000 | 542,062,000 | 481,781,000 | 422,017,042 | 403,712,474 | 370,608,641 | 365,323,608 | 272,432,139 | 269,646,963 | 266,762,568 | 261,608,568 | 259,887,464 | 257,015,699 | 239,998,563 | 216,180,386 | 175,476,521 | 143,661,893 | 111,229,666 | 101,579,618 | 54,037,361 | 53,590,920 | 53,101,402 | 52,604,353 |
| treasury stock | -21,992,000 | -15,117,000 | -8,994,000 | -2,383,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,000 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | -234,337 | ||||
| accumulated deficit | -1,495,947,000 | -1,524,134,000 | -1,529,194,000 | -1,552,525,000 | -1,556,405,000 | -1,525,068,000 | -1,514,361,000 | -1,499,945,000 | -1,613,875,000 | -1,566,265,000 | -1,527,033,000 | -1,474,039,000 | -1,438,221,000 | -1,397,711,000 | -1,328,698,000 | -1,235,359,000 | -1,149,722,000 | -1,071,225,000 | -980,597,000 | -892,379,000 | -805,215,000 | -752,332,000 | -701,216,000 | -661,643,000 | -599,713,000 | -563,501,000 | -528,345,000 | -474,485,000 | -440,534,000 | -396,392,000 | -354,862,832 | -324,003,065 | -292,467,413 | -264,114,329 | -236,386,820 | -212,712,677 | -187,881,650 | -171,982,588 | -158,133,926 | -140,522,114 | -126,866,198 | -109,763,015 | -95,185,280 | -76,388,851 | -58,937,682 | |||||
| total stockholders’ equity | 276,432,000 | 237,289,000 | 222,364,000 | 192,157,000 | 177,568,000 | 160,109,000 | 160,502,000 | 164,769,000 | 40,453,000 | 27,433,000 | 58,587,000 | 100,481,000 | 129,035,000 | 170,386,000 | 237,153,000 | 311,517,000 | 383,130,000 | 445,285,000 | 519,350,000 | 170,658,000 | 194,227,000 | 38,615,000 | 13,205,000 | 19,254,000 | 24,036,000 | 71,744,000 | 101,376,000 | 85,232,000 | 66,993,055 | 79,545,766 | 77,975,018 | 101,041,759 | 35,867,802 | 56,754,721 | 78,701,085 | 89,445,768 | 101,573,302 | 116,311,812 | -891,085 | 566,648 | 2,746,401 | 7,143,612 | ||||||||
| total liabilities and stockholders’ equity | 702,613,000 | 656,689,000 | 577,690,000 | 586,014,000 | 401,207,000 | 373,323,000 | 329,587,000 | 331,067,000 | 220,854,000 | 197,358,000 | 193,572,000 | 217,891,000 | 251,666,000 | 303,028,000 | 379,629,000 | 409,687,000 | 481,400,000 | 548,699,000 | 625,642,000 | 273,856,000 | 294,621,000 | 163,014,000 | 106,585,000 | 117,538,000 | 83,616,000 | 114,374,000 | 140,715,000 | 120,994,000 | 97,381,536 | 101,781,514 | 101,197,751 | 123,256,432 | 54,781,547 | 75,687,094 | 94,797,540 | 100,062,519 | 113,473,201 | 127,407,138 | ||||||||||||
| loan payable | 244,429,000 | 100,118,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| prepaid research and development and other current assets | 7,047,000 | 8,095,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| leasehold interest | 1,362,000 | 1,415,000 | 1,468,000 | 1,521,000 | 1,574,000 | 1,627,000 | 1,680,000 | 1,733,000 | 1,786,000 | 1,839,000 | 1,892,000 | 1,945,000 | 1,998,000 | 2,051,000 | 2,104,000 | 2,157,000 | 2,168,000 | 2,129,000 | 2,157,000 | 2,203,000 | 2,249,000 | 2,294,000 | 2,331,000 | 2,376,000 | 2,397,000 | 2,429,434 | 2,466,202 | 2,479,349 | 2,491,211 | 2,042,281 | 2,517,771 | 1,968,734 | ||||||||||||||||||
| equipment | 66,000 | 95,000 | 133,000 | 206,000 | 237,000 | 307,000 | 376,000 | 447,000 | 526,000 | 600,000 | 600,000 | 597,000 | 488,000 | 481,000 | 378,000 | 331,000 | 320,000 | 282,000 | 275,000 | 237,000 | 241,000 | 251,000 | 268,000 | 265,000 | 252,000 | 248,020 | 268,366 | 289,305 | 307,732 | 328,148 | 327,674 | 34,833 | 24,821 | 20,357 | 7,763 | 7,326 | 8,177 | |||||||||||||
| goodwill | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,000 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | 799,391 | |||||||||
| prepaid research and development | 4,183,000 | 5,001,000 | 4,863,000 | 4,771,000 | 4,237,000 | 4,026,000 | 3,627,000 | 4,092,000 | 11,929,000 | 11,043,000 | 7,728,000 | 5,590,000 | 5,231,000 | 5,540,000 | 3,832,000 | 7,737,000 | 8,105,000 | 7,040,000 | 8,478,000 | 11,120,000 | 9,691,000 | 11,389,000 | 8,890,000 | 6,824,000 | 8,055,486 | 5,022,846 | 9,662,237 | 8,422,375 | 5,678,755 | 10,121,215 | 14,510,025 | 10,979,437 | 9,151,142 | 9,950,893 | 10,921,958 | 9,810,887 | 6,179,743 | 9,117,863 | 3,976,742 | 2,418,995 | ||||||||||
| deferred revenue | 6,016,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| deferred revenue, net of current portion | 229,000 | 267,000 | 305,000 | 343,000 | 381,000 | 419,000 | 457,000 | 495,000 | 533,000 | 571,000 | 610,000 | 648,000 | 686,000 | 724,000 | 762,000 | 800,000 | 838,000 | 876,000 | 914,000 | 952,000 | 990,000 | 1,029,000 | 1,066,667 | 1,104,762 | 1,142,857 | 1,180,953 | 1,219,048 | 1,257,143 | 1,295,238 | 1,333,333 | 1,371,429 | 1,409,524 | 1,447,619 | 1,485,714 | 1,523,810 | 1,561,905 | 1,600,000 | 1,638,095 | ||||||||||||
| loan payable – current portion | ||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term debt | 28,741,000 | 28,513,000 | 28,286,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| right-of-use-assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
| right of use asset | 8,493,000 | 7,659,000 | 7,947,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders’ (deficit) equity | ||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ (deficit) equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ (deficit) equity | -1,353,000 | -25,791,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ (deficit) equity | 101,849,000 | 93,327,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| deferred rent | 1,462,000 | 1,436,000 | 1,411,000 | 1,388,000 | 1,364,601 | 1,341,372 | 1,321,180 | 1,307,063 | 816,257 | 793,968 | 681,720 | 389,554 | ||||||||||||||||||||||||||||||||||||||
| lease liability – non current | 9,380,000 | 8,062,000 | 8,182,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| long-term liabilities | 18,350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| interest receivable | 95,000 | 80,000 | 87,000 | 79,000 | 108,468 | 43,290 | 22,824 | 83,852 | 108,458 | 133,766 | 164,106 | 186,021 | 158,527 | 190,313 | 89,710 | 85,516 | 53,821 | 74,682 | 11,124 | |||||||||||||||||||||||||||||||
| current portion of deferred revenue | 152,000 | 152,000 | 152,000 | 152,000 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | 152,381 | ||||||||||||||||||||||||||||||
| notes payable | 67,000 | 91,000 | 210,000 | 224,000 | 127,614 | 182,156 | 152,568 | 174,657 | 68,875 | 117,126 | 90,564 | 152,917 | 211,549 | 181,668 | 295,360 | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share 10,000,000 shares authorized, none issued and outstanding as of september 30, 2018 and december 31, 2017) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| other assets | 110,067 | 164,375 | 127,700 | 127,700 | 173,841 | 171,182 | 141,717 | 155,564 | 130,626 | 137,101 | 71,251 | 98,365 | 76,415 | 70,506 | 70,506 | 70,506 | 70,506 | |||||||||||||||||||||||||||||||||
| contingently issuable shares | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||||||||||||||||||||||||||||||||||||
| property, plant and equipment | 333,859 | 323,003 | 47,122 | 69,225 | ||||||||||||||||||||||||||||||||||||||||||||||
| prepaid rent | 1,151,163 | |||||||||||||||||||||||||||||||||||||||||||||||||
| liabilities and equity | ||||||||||||||||||||||||||||||||||||||||||||||||||
| equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| total equity | 112,949,732 | 106,230,512 | 80,101,884 | 67,080,192 | 52,095,815 | 54,431,561 | ||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and equity | 123,605,281 | 117,269,251 | 86,746,890 | 77,544,253 | 56,302,299 | 58,173,955 | ||||||||||||||||||||||||||||||||||||||||||||
| 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| notes payable, current portion | 272,206 | 275,190 | 183,144 | 159,214 | ||||||||||||||||||||||||||||||||||||||||||||||
| interest payable | ||||||||||||||||||||||||||||||||||||||||||||||||||
| notes payable, less current portion, at fair value | 115,554 | |||||||||||||||||||||||||||||||||||||||||||||||||
| f-2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| deficit accumulated in the development stage | -46,951,252 | |||||||||||||||||||||||||||||||||||||||||||||||||
| prepaid expenses | 215,852 | 202,161 | 352,657 | 252,092 | ||||||||||||||||||||||||||||||||||||||||||||||
| property and equipment | 44,533 | 52,472 | 62,904 | 74,132 | ||||||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 1,279,485 | 852,490 | 1,001,849 | 1,523,663 | ||||||||||||||||||||||||||||||||||||||||||||||
| accrued expenses | 592,177 | 938,656 | 1,528,406 | 669,247 | ||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, .001 par value. authorized 1,500,000 shares; no shares issued and outstanding at december 31, 2007 and 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| deficit accumulated during the development stage | -54,999,070 | -53,094,896 | -50,425,475 | -45,531,075 | ||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders' equity | 980,577 | 2,357,794 | 5,276,656 | 9,336,522 | ||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, .001 par value. authorized 1,500,000 shares; no shares issued and outstanding at september 30, 2007 and december 31, 2006, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, .001 par value. authorized 1,500,000 shares; no shares issued and outstanding at june 30, 2007 and december 31, 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| subscription receivable | 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, .001 par value. authorized 1,500,000 shares; | ||||||||||||||||||||||||||||||||||||||||||||||||||
| no shares issued and outstanidng at march 31, 2007 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| and december 31, 2006, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 70,333,316 and 60,120,038 shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||||||||
| at march 31, 2007 and december 31, 2006, respectively | 70,334 | |||||||||||||||||||||||||||||||||||||||||||||||||
| see accompanying notes to unaudited condensed consolidated financial statements. |
We provide you with 20 years of balance sheets for TG Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TG Therapeutics. Explore the full financial landscape of TG Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about TG Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.